OBJECTIVES:  This analysis was design to explore the measures of Romanian Ministry of Health for better access to anti-EGFR in Romania, also regarding their availability in clinical practice.  It has been shown that EGFR expression may be reduced at the time of tumor progression when compared to newly diagnosed, untreated disease. METHODS:  : We analyzed the reimbursement lists from 01.01.2015, 01.07.2015, 01.10.2015, 01.11.2015, 01.12.2015 and 01.01.2016. The data was acquiered from the National Healthcare Information system. All anti-EGFR drugs were evaluated, and their prices were compared between the six lists using descriptive analysis. RESULTS:  : The anti-EGFR drugs from the 01.01.2015 were bevacizumab, cetuximab, dasatinib, erlotinib, imatinib, nilotinib, rituximab, ruxolitinib, sorafenib, sunitinib and trastuzumab (from 11 pharmaceutical companies). The manufacturers didn’t prefer a flat pricing model (same price for different dosages). Pharmaceutical costs were reduced with percentages from 7% to 29% on the reimbursement list from 01.07.2015. The smallest decreased price was for erlotinib 100mg and the biggest was for dasatinib 20mg. The use of cost-volume/cost-volume-outcome agreements for 2 new anti-EGFRs has involved their pharmaceutical companies bearing some of the costs of reimbursement. It’s the case of crizotinib and dabrafenib that were included in the reimbursement list from 01.11.2015. The process of assessing new anti-EGFR for conditional inclusion in the reimbursement list has been started with three INNs: afatinib (350 eligible patients), axitinib (400 eligible patients) and lapatinib (500 eligible patients). CONCLUSIONS:  Although these measures are a disappointing outcome for the pharmaceutical industry, the inclusion of new anti-EGFRs into Romania’s reimbursement system ensures a better access (or not because of the parallel trading) for patients with the latest medical findings, while keeping the expenses within the economic situation.